Nanosuspension formulations for low-soluble drugs: pharmacokinetic evaluation using spironolactone as model compound. - Wikidata - awgldk - TriplyDB

Nanosuspension formulations for low-soluble drugs: pharmacokinetic evaluation using spironolactone as model compound.

Nanosuspension formulations for low-soluble drugs: pharmacokinetic evaluation using spironolactone as model compound.

http://www.wikidata.org/entity/Q46437949

about

Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery.Thiomers: forms, functions and applications to nanomedicine.Drug nanoparticles: formulating poorly water-soluble compounds.Thiomers: promising platform for macromolecular drug delivery.Recent advancements in mechanical reduction methods: particulate systems.Drug solubility: importance and enhancement techniques.Evaluation of nanosuspensions for absorption enhancement of poorly soluble drugs: in vitro transport studies across intestinal epithelial monolayers.Preparation, characterization, pharmacokinetics, and tissue distribution of curcumin nanosuspension with TPGS as stabilizer.Fate of nanostructured lipid carriers (NLCs) following the oral route: design, pharmacokinetics and biodistribution.Preparation of fenofibrate nanosuspension and study of its pharmacokinetic behavior in rats.Cefdinir nanosuspension for improved oral bioavailability by media milling technique: formulation, characterization and in vitro-in vivo evaluations.Nanotechnology as Emerging Tool for Enhancing Solubility of Poorly Water-Soluble Drugs Nanocrystals of Poorly Soluble Drugs: Drug Bioavailability and Physicochemical Stability Nanosuspension Technologies for Delivery of Poorly Soluble Drugs

P2860

Q34733880-39086E43-B7FA-42E7-A7C2-981C7964B7CE Q36918044-D59E5308-610A-4794-82CE-092473F0583A Q37109079-EFB7834B-6861-478F-9D31-DEC74FB4688A Q38063302-6303C03E-D8ED-4911-B928-2734D109FB5B Q38132471-50924C10-A941-439B-9765-565358502940 Q41885580-94942144-3DFF-4652-B700-645CE9B31BE3 Q42583413-176617FA-32AE-4305-8F9A-4E6A098C5006 Q43025626-C5BC02D6-A7C9-4E09-AF1D-F5C8AEC22A11 Q45887220-F3B6A9A9-6811-488F-A250-143DB96FF5B8 Q45998080-61422896-200C-4020-BADE-85E92A117620 Q50777721-6C2C4E23-0EA3-4CD1-80DE-B02DE7E3709C Q57343790-76F99C9E-7CAD-44FB-939D-4FE9FA85A5B3 Q58726467-7D049EEA-030F-47A6-809E-5F9107088F38 Q59113220-CEEC0F83-8593-405B-A296-307A5C4AC311

P2860

Nanosuspension formulations for low-soluble drugs: pharmacokinetic evaluation using spironolactone as model compound.

http://www.wikidata.org/entity/Q46437949

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Nanosuspension formulations fo ...... ronolactone as model compound.

@en

Nanosuspension formulations fo ...... ronolactone as model compound.

@nl

type

label

Nanosuspension formulations fo ...... ronolactone as model compound.

@en

Nanosuspension formulations fo ...... ronolactone as model compound.

@nl

prefLabel

Nanosuspension formulations fo ...... ronolactone as model compound.

@en

Nanosuspension formulations fo ...... ronolactone as model compound.

@nl

P1433

Q46437949-C3E8D08C-47FC-4078-ADC1-5621B1840093

P1476

Q46437949-EDDA94CA-0F88-4CDE-B36F-322C5326EFFB

P2093

Q46437949-35A15340-C415-48BF-8F6D-D40DE54BE53C

Q46437949-3D935D4F-393B-4D52-8E8B-8C67C09944CD

Q46437949-469692EE-3EC6-47A4-9DB8-69524BCFAEC5

Q46437949-48E13D5B-EBF0-409A-BE8D-807BB1D5FCF9

Q46437949-5539C3EE-E21E-447F-AEAE-BFADC89DE5A5

Q46437949-5F54BA58-4C3F-421B-85FD-F6BD88CB41A5

Q46437949-62D2C0E7-7B81-47E9-A0E0-CED138D132AB

Q46437949-BAC5E4E0-C723-4E2C-918A-8C4A5301073F

P2860

Q46437949-02FFDC4B-9DBA-434A-BC9A-CDB1946E1E4B

Q46437949-2B38026F-46B9-4114-982D-126CD6932D04

Q46437949-7C907D7F-9EDA-4E50-8BCF-D594FF054C09

Q46437949-8090DDFB-B659-4E95-8A1F-413763EB1C5B

Q46437949-A4F51A53-BCEF-40DD-81BD-8FA087325CB6

Q46437949-BA3E292A-CCB0-424C-96DC-A0921169AAC0

Q46437949-ECBE0E10-95F9-40E9-8FA0-4A84C5682F6D

P304

Q46437949-BAAD2C60-9D0D-46DB-AC96-A9298CDA6B4E

P31

Q46437949-A1A36A30-BD9C-4FD0-BEE3-247A7B81F674

P356

Q46437949-F50F78F3-6B04-4441-A3F0-C03C332BB420

P407

Q46437949-2904C42B-760F-49C2-959D-1EB3C4749C14

P433

Q46437949-8F9D6487-FF69-4BBD-AE76-CB856E4F3391

P478

Q46437949-4A500E6E-13C8-48F8-AC8A-3A6D1D0D9C3B

P577

Q46437949-F8523E92-B451-4F8B-9010-7778A14DDF52

P698

Q46437949-C7D5FEEC-D382-478E-9B68-8F7D36F3A266

P356

P1433

Drug Development and Industrial Pharmacy

P1476

Nanosuspension formulations fo ...... ronolactone as model compound.

@en

P2093

Frenzel D

http://www.w3.org/2001/XMLSchema#string

Grenier P

http://www.w3.org/2001/XMLSchema#string

Hanafy A

http://www.w3.org/2001/XMLSchema#string

Langguth P

http://www.w3.org/2001/XMLSchema#string

Nhamias A

http://www.w3.org/2001/XMLSchema#string

Ohlig T

http://www.w3.org/2001/XMLSchema#string

Spahn-Langguth H

http://www.w3.org/2001/XMLSchema#string

Vergnault G

http://www.w3.org/2001/XMLSchema#string

P2860

pH-Dependent dissolving nano- and microparticles for improved peroral delivery of a highly lipophilic compound in dogs

Transfer of lipophilic markers from PLGA and polystyrene nanoparticles to caco-2 monolayers mimics particle uptake.

Influence of food on the bioavailability of spironolactone.

Nanosizing: a formulation approach for poorly-water-soluble compounds.

Nanoparticle engineering processes for enhancing the dissolution rates of poorly water soluble drugs.

The metabolism and biopharmaceutics of spironolactone in man.

Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability.

P304

319-329

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1081/DDC-52182

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P577

2005-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15830727

http://www.w3.org/2001/XMLSchema#string